Last reviewed 2026-04-19 · How we verify

administration of UI018

Korea United Pharm. Inc. · Phase 1 active Small molecule

administration of UI018 is a Small molecule drug developed by Korea United Pharm. Inc.. It is currently in Phase 1 development.

At a glance

Generic name	administration of UI018
Sponsor	Korea United Pharm. Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Safety and PK of UI018 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

administration of UI018 CI brief — competitive landscape report
administration of UI018 updates RSS · CI watch RSS
Korea United Pharm. Inc. portfolio CI

Frequently asked questions about administration of UI018

What is administration of UI018?

administration of UI018 is a Small molecule drug developed by Korea United Pharm. Inc..

Who makes administration of UI018?

administration of UI018 is developed by Korea United Pharm. Inc. (see full Korea United Pharm. Inc. pipeline at /company/korea-united-pharm-inc).

What development phase is administration of UI018 in?

administration of UI018 is in Phase 1.

Manufacturer: Korea United Pharm. Inc. — full pipeline
Compare: administration of UI018 vs similar drugs
Pricing: administration of UI018 cost, discount & access